Published in Clinical Trials Week, June 27th, 2005
The COSTAR II trial is designed to randomize approximately 1,700 patients at up to 75 U.S. sites and 15 international sites. Conor expects the data from this trial to support its application for U.S. regulatory approval of Conor's CoStar cobalt chromium paclitaxel-eluting stent. The first patient procedure was performed by Dean J. Kereiakes, MD, FACC, medical director of The Heart Center of Greater Cincinnati...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Clinical Trials Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.